Drug Profile
TCB 006
Alternative Names: Autologous gamma delta CAR T-cell therapy - bluebird bio/TC BioPharm; B7-H4 CAR-T; TCB-006Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator TC BioPharm
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom (Parenteral)
- 25 Feb 2019 TC BioPharm plans a clinical trial for Solid tumours, in late 2019
- 25 Feb 2019 TC BioPharm collaborates with Trinity College Dublin to develop V delta 1 γδ T cells for Solid tumours